Home > Our History

Our History

20 Years of DCVMN: A Timeline

2000

WHO meeting of International Public Sector Vaccinology Institutions in Geneva on March 2000, called vaccine manufacturers from developing countries to form a constituency and holds 1st AGM in Noordwick.

More

2001

DCVMN met on 26–27 April 2001 in Bandung, Indonesia, formalizing strategic objectives and governance and grows to 20 members.

More

2002

A DCVMN member engaged in an historical Project to develop a vaccine for the African meningitis belt countries.

More

2003
2004

Success in increasing access to HepB and Hib containing DPT combination vaccines with the help from technology transfer from The Netherlands Vaccine Institute (NVI) to three DCVMN member companies: Bio Farma, Serum Institute of India and Biological E.

DCVMN had 19 members in 2004

More

2005

DCVMN had 29 members in 2005, with 7 pre-qualified vaccines.

More

2006

DCVMN members engaged on the Global Action Plan for Influenza Vaccines. In response to the human-to-human transmission of H5N1, WHO called to strengthen the capacity of developing countries to produce influenza vaccines.

More

2007

The Network’s main strategic priority, to increase access to combination vaccines containing DPT-HepatitisB-Haemophilus influenzae type b (Hib), has been fulfilled due, in part, to the transfer of conjugation technology from The Netherlands Vaccine Institute to various manufacturers.

More

2008

The first fully liquid Pentavalent (DTwPHepBHib) for Childhood vaccination was launched by Panacea Biotec and granted WHO pre-qualification for Gavi supply.

DCVMN had 19 members; 7 members with WHO pre-qualified vaccines.

More

2008

DCVMN members – Serum Institute of India, China National Biotec Group, Panacea, Beijing Minhai, LG Chem - engaged in the Sabin-IPV vaccine development upon request of WHO.

More

WHO declares the start of 2009 influenza pandemic

2009

In the context of the H1N1 Pandemic, three DCVMs readied an influenza vaccine for global use in a record time of 9 months.

More

2009

Last endemic case of rubella in the Americas observed in February 2009, with the help of the consistent supply of Rubella containing vaccines from Serum Institute of India and Biomanguinhos

DCVMN had 23 members

More

2010

The group A meningitis vaccine produced by a DCVM, SII, was approved for use in Sub-Saharan Africa, resulting in 100 million people being vaccinated.

DCVMN had 22 members

More

2011

On 13 January 2011, India recorded its last case of poliomyelitis.

2012

The first Hepatitis E Vaccine produced by INNOVAX was approved in China.

The DCVMN International Secretariat in Switzerland was formally established on February 15th, 2012 as a not-for-profit international association of vaccine manufacturers.

More

2013

Japanese encephalitis vaccines from DCVMs -Chengdu Biological Products Institute and from Biological E - received WHO pre-qualification.

Bharat Biotech launched the first typhoid conjugate vaccine.

More

2014

Executives of the Developing Countries Vaccine Manufacturers Network met Dr. Margaret Chan, WHO Director General.

More

2015

The first Sabin-based IPV vaccine was developed by IMBCAMS and approved in China.

More

2016

The first inactivated Enterovirus 71 vaccine was launched by IMBCAMS and approved for the distribution to the Chinese market.

More

2017

The first fully liquid hexavalent vaccine based on whole-cell Pertussis was produced by Panacea Biotec.

More

2018

Two new Rotavirus vaccines from Serum Institute of India and Bharat Biotech received WHO pre-qualification.

More

2019

A pneumococcal vaccine produced by Serum Institute of India received WHO pre-qualification. Since 2008, SII and PATH have collaborated to develop the vaccine, with support from the Bill & Melinda Gates Foundation.

More

2020

On 25th August 2020, the Africa Regional Certification Commission certified the WHO African Region as wild polio-free after four years without a case.

The first vaccine granted WHO Emergency Use. WHO listed the nOPV2 vaccine from Bio Farma, Indonesia, for emergency use to address cases of a vaccine-derived polio strain in African and East Mediterranean countries.

More

2021

Partners: